Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 8/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.49 |
| ▸ | BRAF | P15056 | 10/20 | 0.48 |
| ▸ | RAF1 | P04049 | 8/20 | 0.48 |
| ▸ | KDR | P35968 | 3/20 | 0.48 |
| ▸ | INSR | P06213 | 2/20 | 0.47 |
| ▸ | LYN | P07948 | 2/20 | 0.47 |
| ▸ | HCK | P08631 | 2/20 | 0.47 |
| ▸ | SRC | P12931 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL374295 | 0.91 | LCK (0.53) | LCKMAPK14BRAFRAF1KDR | |
| SCHEMBL374105 | 0.88 | LCK (0.55) | LCKMAPK14BRAFRAF1KDR | |
| SCHEMBL374431 | 0.84 | LCK (0.60) | LCKMAPK14BRAFKDRINSR | |
| SCHEMBL374560 | 0.84 | LCK (0.56) | LCKMAPK14BRAFRAF1KDR | |
| SCHEMBL374342 | 0.82 | RAF1 (0.56) | LCKMAPK14BRAFRAF1KDR | |
| SCHEMBL374318 | 0.82 | CSF1R (0.54) | LCKBRAFRAF1KDRINSR | |
| SCHEMBL374565 | 0.81 | LCK (0.54) | LCKMAPK14BRAFRAF1KDR | |
| SCHEMBL374676 | 0.81 | LCK (0.61) | LCKMAPK14BRAFRAF1KDR | |
| SCHEMBL15435488 | 0.80 | LCK (0.53) | LCKMAPK14BRAFRAF1EPHX2 | |
| SCHEMBL374367 | 0.80 | LCK (0.62) | LCKMAPK14BRAFRAF1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2409969-B1 | Pyrimidine urea derivatives as kinase inhibitors | NOVARTIS AG (CH) | 2013-07-24 | — | — | EP | claimed |
| EP-2409969-A1 | Pyrimidine urea derivatives as kinase inhibitors | Novartis AG (CH) | 2012-01-25 | — | — | EP | claimed |
| JP-2008503537-A | — | — | 2008-02-07 | — | — | JP | claimed |
| EP-1761505-A1 | PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS | Novartis AG (CH) | 2007-03-14 | — | — | EP | claimed |
| WO-2006000420-A1 | PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-01-05 | — | — | WO | claimed |
| WO-2023225534-A1 | AROMATIC BORON-CONTAINING COMPOUNDS AND RELATED INSULIN ANALOGS | PROTOMER TECHNOLOGIES INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| EP-4247429-A1 | AROMATIC BORON-CONTAINING COMPOUNDS AND INSULIN ANALOGS | Protomer Technologies Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-4126058-A1 | CONJUGATES FOR SELECTIVE RESPONSIVENESS TO VICINAL DIOLS | Protomer Technologies Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| WO-2022109078-A1 | AROMATIC BORON-CONTAINING COMPOUNDS AND INSULIN ANALOGS | PROTOMER TECHNOLOGIES INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2021202802-A1 | CONJUGATES FOR SELECTIVE RESPONSIVENESS TO VICINAL DIOLS | PROTOMER TECHNOLOGIES INC. (US) | 2021-10-07 | — | — | WO | disclosed |
| EP-2925345-B1 | METHOD FOR MAKING O-GLYCOSYLATED CARBOXY TERMINAL PORTION (CTP) PEPTIDE-BASED INSULIN AND INSULIN ANALOGUES | MERCK SHARP & DOHME (US) | 2018-09-05 | — | — | EP | disclosed |
| EP-3291828-A1 | GLUCOSE RESPONSIVE INSULINS | Mahdavi, Alborz (US) | 2018-03-14 | — | — | EP | disclosed |
| WO-2010088286-A1 | SYNTHETIC CONJUGATES AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| US-20090137804-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2009-05-28 | — | — | US | disclosed |
| US-20090137804-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2009-05-28 | — | — | US | disclosed |
| US-20090137804-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2009-05-28 | — | — | US | disclosed |
| EP-1761505-A1 | PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS | Novartis AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006000420-A1 | PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-01-05 | — | — | WO | disclosed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137804-A1 | Compounds and Compositions as Protein Kinase Inhibitors | MAP3K20, MAP3K1, CDK1 | LCK 120/4885MAPK14 325/4885BRAF 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.